Antibody-drug conjugate

Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 13, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Companies, Daiichi Sankyo, MedWatch, Medicine, Economy of Japan, Immunology, Antibody-drug conjugate

Company executives will provide an overview of the ASCO research data, updates for the oncology portfolio and address questions from investors and analysts.

Key Points: 
  • Company executives will provide an overview of the ASCO research data, updates for the oncology portfolio and address questions from investors and analysts.
  • May 13 at 5:00 PM ET
    The DXd ADC portfolio of Daiichi Sankyo currently consists of seven novel antibody drug conjugates (ADCs) with four in clinical development across multiple types of cancer.
  • Each ADC is engineered using Daiichi Sankyos proprietary and portable DXd ADC technology to target and deliver chemotherapy inside cancer cells that express a specific cell surface antigen.
  • To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc, at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 13, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Antibody-drug conjugates, Gemtuzumab ozogamicin, Antibody-drug conjugate, Loncastuximab tesirine

The "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development of anti cancer therapeutics market.
  • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
    Marketed Cancer Antibody Drug Conjugate: 9 Drugs
    Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
    USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
    Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
    After the approval of first ADC i.e.
  • Further, the Mylotarg was also reintroduced into the market in 2017 and currently 9 cancer antibody drug conjugates are available in the market, which are continuously boosting the drug conjugates market.

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Retrieved on: 
Friday, May 8, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Immunology, Medicine, Clinical medicine, Branches of biology, Biotechnology, Zymeworks, Antibody-drug conjugate, Antibody

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.

Key Points: 
  • Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
  • Zymeworks lead clinical candidate, ZW25, is a novel Azymetric bispecific antibody currently in Phase 2 clinical development.
  • Zymeworks second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks proprietary ZymeLink linker-cytotoxin.

Immunomedics to Participate in BofA Securities 2020 Health Care Conference

Retrieved on: 
Thursday, May 7, 2020
Cancer treatments, Immunomedics, Clinical medicine, Medicine, Monoclonal antibodies, Biotechnology, Antibody-drug conjugate, ADC, Antibody-drug conjugates, Sacituzumab govitecan, Milatuzumab

MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 2:20 p.m. Eastern Time.

Key Points: 
  • MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 2:20 p.m. Eastern Time.
  • Live audio webcast of the fireside chat will be accessible and available for replay from the Companys website at https://immunomedics.com/investors/ .
  • The Company will also participate in virtual one-on-one meetings with institutional investors.
  • Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference

Retrieved on: 
Wednesday, May 6, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Cancer treatments, Medicine, Clinical medicine, Immunology, ImmunoGen, Antineoplastic drugs, Antibody-drug conjugate, Monoclonal antibodies, Antibody-drug conjugates

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming RBC Capital Markets Global Healthcare Virtual Conference.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming RBC Capital Markets Global Healthcare Virtual Conference.
  • The presentation is scheduled for May 19, 2020 at 10:20am ET.
  • A webcast of the presentation will be accessible through the Investors and Media section of the Company's website on www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients.

Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

Retrieved on: 
Wednesday, May 6, 2020
Health, General Health, Branches of biology, Life sciences, Articles, Biotechnology, Applied genetics, Antineoplastic drugs, Immunology, Virotherapy, Gene therapy, Therapy, Antibody-drug conjugate, Lentivirus, Magenta Therapeutics, AVROBIO

(Nasdaq: AVRO) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIOs investigational lentiviral gene therapies.

Key Points: 
  • (Nasdaq: AVRO) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIOs investigational lentiviral gene therapies.
  • Under the collaboration, Magenta and AVROBIO will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIOs investigational gene therapies.
  • This partnership will allow Magenta to validate our conditioning platform in lentiviral gene therapy applications, said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics.
  • We have optimized our ADCs for gene therapy and transplant settings and look forward to collaborating with AVROBIO to evaluate MGTA-117 in specific gene therapy settings.

AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

Retrieved on: 
Wednesday, May 6, 2020
Research, FDA, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Branches of biology, Life sciences, Articles, Biotechnology, Antineoplastic drugs, Immunology, Gene therapy, Antibody-drug conjugate, Therapy, AVROBIO, Magenta Therapeutics

(Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIOs investigational lentiviral gene therapies.

Key Points: 
  • (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIOs investigational lentiviral gene therapies.
  • Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIOs investigational gene therapies.
  • We believe targeted ADCs represent the next generation of medicines to prepare patients for gene therapy or transplant in a targeted, precise way.
  • This partnership will allow Magenta to validate our conditioning platform in lentiviral gene therapy applications, said Jason Gardner, D.Phil., president and chief executive officer, Magenta Therapeutics.

Immunomedics Announces Commercial Availability of TRODELVY™ in the United States

Retrieved on: 
Monday, May 4, 2020
Medicine, Medical specialties, Clinical medicine, Immunology, Biotechnology, Breakthrough therapy, Sacituzumab govitecan, Immunomedics, Antibody-drug conjugate, Monoclonal antibody, Antibody, Breast cancer

We are excited to have Trodelvy rapidly available upon FDA approval, an important first step in our drive to gain brand awareness and adoption by healthcare providers, said Brendan Delaney, Chief Commercial Officer of Immunomedics.

Key Points: 
  • We are excited to have Trodelvy rapidly available upon FDA approval, an important first step in our drive to gain brand awareness and adoption by healthcare providers, said Brendan Delaney, Chief Commercial Officer of Immunomedics.
  • In so doing, we hope to establish Immunomedics as a trusted and differentiated partner within the breast cancer community.
  • Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, commented, Todays announcement marks an important milestone for Immunomedics as we have, for the first time in the Companys history, commercially launched a therapeutic product.
  • Trodelvy (sacituzumab govitecan-hziy) is the lead product and the most advanced program in Immunomedics unique antibody-drug conjugate (ADC) platform.

ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results

Retrieved on: 
Friday, May 1, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Immunology, Medicine, Clinical medicine, Biotechnology, Health, Antibody-drug conjugate, ImmunoGen, ImmunoGen

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2020.

Key Points: 
  • ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2020.
  • Through these efforts, we seek to maintain the momentum we have generated in the business throughout 2020.
  • Operating expenses for the first quarter of 2020 were $37.1 million, compared with $50.2 million for the same quarter in 2019.
  • The decrease was driven by R&D expenses, which were $27.4 million for the first quarter of 2020 compared with $38.9 million for the first quarter of 2019.

Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020

Retrieved on: 
Thursday, April 30, 2020
Cancer treatments, Clinical medicine, Medicine, Immunomedics, Antibody-drug conjugate, Lluís Companys, ADC, Monoclonal antibodies, Antibody-drug conjugates

To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 9146008.

Key Points: 
  • To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 9146008.
  • The conference call will be webcast via the Investors page on the Companys website at https://immunomedics.com/investors/ .
  • Approximately two hours following the live event, a webcast replay of the conference call will be available on the Companys website for approximately 30 days.
  • Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.